152 related articles for article (PubMed ID: 36444764)
41. Ductal Carcinoma In Situ - Quo Vadis?
Peltecu G
Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
[TBL] [Abstract][Full Text] [Related]
42. Intraductal fulvestrant for therapy of ERα-positive ductal carcinoma in situ of the breast: a preclinical study.
Wang G; Chen C; Pai P; Korangath P; Sun S; Merino VF; Yuan J; Li S; Nie G; Stearns V; Sukumar S
Carcinogenesis; 2019 Jul; 40(7):903-913. PubMed ID: 31046118
[TBL] [Abstract][Full Text] [Related]
43. Randomized, double-blind, placebo-controlled trial of Cimicifuga racemosa (black cohosh) in women with anxiety disorder due to menopause.
Amsterdam JD; Yao Y; Mao JJ; Soeller I; Rockwell K; Shults J
J Clin Psychopharmacol; 2009 Oct; 29(5):478-83. PubMed ID: 19745648
[TBL] [Abstract][Full Text] [Related]
44. Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.
Groen EJ; van der Noordaa MEM; Schaapveld M; Sonke GS; Mann RM; van Ramshorst MS; Lips EH; Vrancken Peeters MTFD; van Duijnhoven FH; Wesseling J
Breast Cancer Res Treat; 2021 Aug; 189(1):213-224. PubMed ID: 33945043
[TBL] [Abstract][Full Text] [Related]
45. Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ.
Estévez LG; Suarez-Gauthier A; García E; Miró C; Calvo I; Fernández-Abad M; Herrero M; Marcos M; Márquez C; Lopez Ríos F; Perea S; Hidalgo M
Breast Cancer Res; 2014 Sep; 16(4):R76. PubMed ID: 25186428
[TBL] [Abstract][Full Text] [Related]
46. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
[TBL] [Abstract][Full Text] [Related]
47. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial.
Vrieling C; van Werkhoven E; Maingon P; Poortmans P; Weltens C; Fourquet A; Schinagl D; Oei B; Rodenhuis CC; Horiot JC; Struikmans H; Van Limbergen E; Kirova Y; Elkhuizen P; Bongartz R; Miralbell R; Morgan DA; Dubois JB; Remouchamps V; Mirimanoff RO; Hart G; Collette S; Collette L; Bartelink H;
JAMA Oncol; 2017 Jan; 3(1):42-48. PubMed ID: 27607734
[TBL] [Abstract][Full Text] [Related]
48. Clinic-Pathological Features of Breast Ductal Carcinoma
Zheng J; Zhou T; Li F; Shi J; Zhang L
Cancer Invest; 2020 Feb; 38(2):113-121. PubMed ID: 31939679
[No Abstract] [Full Text] [Related]
49. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
50. High EZH2 expression in ductal carcinoma in situ diagnosed on breast core needle biopsy is an independent predictive factor for upgrade on surgical excision.
Genco IS; Ozgultekin B; Hosseini H; Hackman K; Ferreira L; Santagada E; Wahl S; Hajiyeva S
Pathol Res Pract; 2020 Dec; 216(12):153283. PubMed ID: 33197837
[TBL] [Abstract][Full Text] [Related]
51. Preoperative clinicopathologic factors and breast magnetic resonance imaging features can predict ductal carcinoma in situ with invasive components.
Lee CW; Wu HK; Lai HW; Wu WP; Chen ST; Chen DR; Chen CJ; Kuo SJ
Eur J Radiol; 2016 Apr; 85(4):780-9. PubMed ID: 26971424
[TBL] [Abstract][Full Text] [Related]
52. Discriminating low-grade ductal carcinoma in situ (DCIS) from non-low-grade DCIS or DCIS upgraded to invasive carcinoma: effective texture features on ultrafast dynamic contrast-enhanced magnetic resonance imaging.
Mori N; Abe H; Mugikura S; Miyashita M; Mori Y; Oguma Y; Hirasawa M; Sato S; Takase K
Breast Cancer; 2021 Sep; 28(5):1141-1153. PubMed ID: 33900583
[TBL] [Abstract][Full Text] [Related]
53. Is there 'progression through grade' in ductal invasive breast cancer?
Schymik B; Buerger H; Krämer A; Voss U; van der Groep P; Meinerz W; van Diest PJ; Korsching E
Breast Cancer Res Treat; 2012 Oct; 135(3):693-703. PubMed ID: 22886478
[TBL] [Abstract][Full Text] [Related]
54. Black cohosh (Cimicifuga racemosa) relaxes the isolated rat thoracic aorta through endothelium-dependent and -independent mechanisms.
Kim EY; Lee YJ; Rhyu MR
J Ethnopharmacol; 2011 Nov; 138(2):537-42. PubMed ID: 22001858
[TBL] [Abstract][Full Text] [Related]
55. Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?
Pilewskie M; Stempel M; Rosenfeld H; Eaton A; Van Zee KJ; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3487-3493. PubMed ID: 27172775
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of the transition of ductal carcinoma in situ to invasive ductal carcinoma by a Gemini vitamin D analog.
Wahler J; So JY; Kim YC; Liu F; Maehr H; Uskokovic M; Suh N
Cancer Prev Res (Phila); 2014 Jun; 7(6):617-26. PubMed ID: 24691501
[TBL] [Abstract][Full Text] [Related]
57. Systematic Review of Black Cohosh (
Fan CW; Cieri-Hutcherson NE; Hutcherson TC
J Pharm Pract; 2022 Dec; 35(6):991-999. PubMed ID: 33926292
[TBL] [Abstract][Full Text] [Related]
58. The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS).
Al-Kawaz A; Ali R; Toss MS; Miligy IM; Mohammed OJ; Green AR; Madhusudan S; Rakha EA
Breast Cancer Res Treat; 2021 Nov; 190(1):39-51. PubMed ID: 34406589
[TBL] [Abstract][Full Text] [Related]
59. Antiestrogenic activities of Cimicifuga racemosa extracts.
Zierau O; Bodinet C; Kolba S; Wulf M; Vollmer G
J Steroid Biochem Mol Biol; 2002 Jan; 80(1):125-30. PubMed ID: 11867271
[TBL] [Abstract][Full Text] [Related]
60. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ.
Rakovitch E; Nofech-Mozes S; Hanna W; Narod S; Thiruchelvam D; Saskin R; Spayne J; Taylor C; Paszat L
Br J Cancer; 2012 Mar; 106(6):1160-5. PubMed ID: 22361634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]